To further support the increased release of cytochrome c in AML cells following the treatment with AZD5991 in combination with FLT3 inhibitors, we also found increased mitochondrial ROS in the FLT3-mutated AML cells post AZD5991 and FLT3 inhibitor treatments (Figure S6). The gene discussed is FLT3; the disease is acute myeloid leukemia.